Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response

Grafanaki, Katerina; Grammatikakis, Ioannis; Ghosh, Arin; Gopalan, Vishaka; Olgun, Gulden; Liu, Huaitian; Kyriakopoulos, George; Skeparnias, Ilias; Georgiou, Sophia; Stathopoulos, Constantinos; Hannenhalli, Sridhar; Merlino, Glenn; Marie, Kerrie L.; Day, Chi-Ping

doi:10.1016/j.pharmthera.2023.108466

Cited by 10 publications

(6 citation statements)

References 151 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…International Publisher [10][11][12][13][14]. LncRNAs have been found to be involved in a variety of biological processes, can act as oncogenes or tumor suppressors, and are associated with various aspects of cancer, including tumorigenesis, metastasis, and treatment resistance [15][16][17][18][19].…”

Section: Ivyspringmentioning

confidence: 99%

LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies

Wang,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers pose a significant global health challenge, characterized by a high incidence and poor prognosis. The delayed detection and occurrence of metastasis contribute to the overall low survival rates associated with these cancers. Therefore, there is an urgent need to identify novel molecular targets for effective GI cancer treatment. Recent research has shed light on the potential of long non-coding RNAs (lncRNAs) as promising targets in cancer therapy, given their strong association with carcinogenesis and profound impact on tumor development. Among these lncRNAs, lncRNA-MUF, also known as LINC00941, has emerged as a key player in oncogenic regulation, specifically implicated in the progression of various GI cancers, including esophageal, gastric, colorectal, hepatic, and pancreatic cancer. This review aims to provide an updated and focused analysis of the regulatory roles of LINC00941 in the initiation and progression of GI cancer. Our objective is to unravel the underlying molecular mechanisms through which LINC00941 influences GI cancer phenotypes both in vivo and in vitro, with a special emphasis on the key molecules and signaling pathways involved. Additionally, LINC00941 has demonstrated clinical significance in terms of clinical pathology, prognosis, and diagnosis in GI tumors, further reinforcing its potential as a novel therapeutic target.

show abstract

Section: Ivyspringmentioning

confidence: 99%

LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies

Wang,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

show abstract

“…[29] Further classifications of lncRNAs exist based on their structural characteristics, delineating them as either linear lncRNAs or circular lncRNAs. [30] Another classification criterion is the role of lncRNAs in gene expression regulation, which subsets them as either cis-lncRNAs, acting on nearby genomic loci, or trans-lncRNAs, exerting regulatory effects on distant genetic regions. Moreover, ncRNAs exhibit variability in subcellular localization, with examples including small nuclear RNAs and cytoplasm-located siRNAs.…”

Section: Introductionmentioning

confidence: 99%

Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review

Xu,

Zhang

et al. 2024

Medicine

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare and highly aggressive endocrine malignancy. Although surgery can cure localized disease, but the majority of patients experience recurrence of ACC. The 5-year survival rate of patients with metastatic ACC is <15%, and the prognosis is poor. Therefore, it is urgent to explore the potential diagnostic markers and therapeutic targets for ACC. Recently, it has been proved that non-coding RNA (ncRNAs) is widely involved in pathological and physiological processes, including tumorigenesis and development. Aberrantly expressed ncRNAs have been found to be involved in the pathogenesis of ACC. Here, we summarized the expression patterns and the molecular mechanism of the involvement of microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) in ACC development. To explore the clinical value of ncRNAs as noninvasive biomarkers of ACC, we also displayed the relationship between the expression level of ncRNAs and the diagnosis and prognosis of patients with ACC.

show abstract

“…Cancer, including melanoma and colorectal carcinoma, is currently a serious health challenge worldwide. [1][2][3] Timely surgery, chemotherapy, and radiotherapy are the main strategies for cancer treatment. 4 To date, immunotherapy using RNA molecules, immunostimulatory agents, and immune-checkpoint inhibitors has become an increasingly common type of antitumor treatment.…”

Section: Introductionmentioning

confidence: 99%

Staphylococcus Aureus Membrane Vesicles Kill Tumor Cells Through a Caspase-1-Dependent Pyroptosis Pathway

Li,

Wang,

Liu

et al. 2024

IJN

View full text Add to dashboard Cite

Introduction Nanosized outer membrane vesicles (OMVs) from Gram-negative bacteria have attracted increasing interest because of their antitumor activity. However, the antitumor effects of MVs isolated from Gram-positive bacteria have rarely been investigated. Methods MVs of Staphylococcus aureu s USA300 were prepared and their antitumor efficacy was evaluated using tumor-bearing mouse models. A gene knock-in assay was performed to generate luciferase Antares2–MVs for bioluminescent detection. Cell counting kit-8 and lactic dehydrogenase release assays were used to detect the toxicity of the MVs against tumor cells in vitro. Active caspase-1 and gasdermin D (GSDMD) levels were determined using Western blot, and the tumor inhibition ability of MVs was determined in B16F10 cells treated with a caspase-1 inhibitor. Results The vesicular particles of S. aureus USA300 MVs were 55.23 ± 8.17 nm in diameter, and 5 μg of MVs remarkably inhibited the growth of B16F10 melanoma in C57BL/6 mice and CT26 colon adenocarcinoma in BALB/c mice. The bioluminescent signals correlated well with the concentrations of the engineered Antares2–MVs (R 2 = 0.999), and the sensitivity for bioluminescence imaging was 4 × 10 −3 μg. Antares2–MVs can directly target tumor tissues in vivo, and 20 μg/mL Antares2–MVs considerably reduced the growth of B16F10 and CT26 tumor cells, but not non-carcinomatous bEnd.3 cells. MV treatment substantially increased the level of active caspase-1, which processes GSDMD to trigger pyroptosis in tumor cells. Blocking caspase-1 activation with VX-765 significantly protected tumor cells from MV killing in vitro and in vivo. Conclusion S. aureus MVs can kill tumor cells by activating the pyroptosis pathway, and the induction of pyroptosis in tumor cells is a promising strategy for cancer treatment.

show abstract

Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response

Cited by 10 publications

References 151 publications

LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies

LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies

Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review

Staphylococcus Aureus Membrane Vesicles Kill Tumor Cells Through a Caspase-1-Dependent Pyroptosis Pathway

Contact Info

Product

Resources

About